Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG GENES KEGG PATHWAY KEGG DRUG DrugBank 指定難病告示番号
1 CHRNA1 1件: Neuroactive ligand-receptor interaction D03365 Nicotine 1件: 84
2 CHRNA1 1件: Neuroactive ligand-receptor interaction D05156 Nicotine 1件: 84
3 CHRNA1 1件: Neuroactive ligand-receptor interaction D05157 Nicotine 1件: 84
4 CHRNA2 1件: Neuroactive ligand-receptor interaction D03365 Nicotine 1件: 84
5 CHRNA2 1件: Neuroactive ligand-receptor interaction D05156 Nicotine 1件: 84
6 CHRNA2 1件: Neuroactive ligand-receptor interaction D05157 Nicotine 1件: 84
7 CHRNA3 3件: Neuroactive ligand-receptor interaction, Cholinergic synapse, Chemical carcinogenesis - receptor activation D03365 Nicotine 3件: 6, 13, 84
8 CHRNA3 3件: Neuroactive ligand-receptor interaction, Cholinergic synapse, Chemical carcinogenesis - receptor activation D05156 Nicotine 3件: 6, 13, 84
9 CHRNA3 3件: Neuroactive ligand-receptor interaction, Cholinergic synapse, Chemical carcinogenesis - receptor activation D05157 Nicotine 3件: 6, 13, 84
10 CHRNA4 4件: Neuroactive ligand-receptor interaction, Cholinergic synapse, Nicotine addiction, Chemical carcinogenesis - receptor activation D03365 Nicotine 3件: 6, 13, 84
11 CHRNA4 4件: Neuroactive ligand-receptor interaction, Cholinergic synapse, Nicotine addiction, Chemical carcinogenesis - receptor activation D05156 Nicotine 3件: 6, 13, 84
12 CHRNA4 4件: Neuroactive ligand-receptor interaction, Cholinergic synapse, Nicotine addiction, Chemical carcinogenesis - receptor activation D05157 Nicotine 3件: 6, 13, 84
13 CHRNA5 1件: Neuroactive ligand-receptor interaction D03365 Nicotine 1件: 84
14 CHRNA5 1件: Neuroactive ligand-receptor interaction D05156 Nicotine 1件: 84
15 CHRNA5 1件: Neuroactive ligand-receptor interaction D05157 Nicotine 1件: 84
16 CHRNA7 7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Chemical carcinogenesis - receptor activation D03365 Nicotine 3件: 6, 13, 84
17 CHRNA7 7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Chemical carcinogenesis - receptor activation D05156 Nicotine 3件: 6, 13, 84
18 CHRNA7 7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Chemical carcinogenesis - receptor activation D05157 Nicotine 3件: 6, 13, 84
19 CHRNB1 1件: Neuroactive ligand-receptor interaction D03365 Nicotine 1件: 84
20 CHRNB1 1件: Neuroactive ligand-receptor interaction D05156 Nicotine 1件: 84
21 CHRNB1 1件: Neuroactive ligand-receptor interaction D05157 Nicotine 1件: 84
22 CHRNB2 4件: Neuroactive ligand-receptor interaction, Cholinergic synapse, Nicotine addiction, Chemical carcinogenesis - receptor activation D03365 Nicotine 3件: 6, 13, 84
23 CHRNB2 4件: Neuroactive ligand-receptor interaction, Cholinergic synapse, Nicotine addiction, Chemical carcinogenesis - receptor activation D05156 Nicotine 3件: 6, 13, 84
24 CHRNB2 4件: Neuroactive ligand-receptor interaction, Cholinergic synapse, Nicotine addiction, Chemical carcinogenesis - receptor activation D05157 Nicotine 3件: 6, 13, 84
25 CHRNB3 1件: Neuroactive ligand-receptor interaction D03365 Nicotine 1件: 84
26 CHRNB3 1件: Neuroactive ligand-receptor interaction D05156 Nicotine 1件: 84
27 CHRNB3 1件: Neuroactive ligand-receptor interaction D05157 Nicotine 1件: 84
28 CHRNB4 3件: Neuroactive ligand-receptor interaction, Cholinergic synapse, Chemical carcinogenesis - receptor activation D03365 Nicotine 3件: 6, 13, 84
29 CHRNB4 3件: Neuroactive ligand-receptor interaction, Cholinergic synapse, Chemical carcinogenesis - receptor activation D05156 Nicotine 3件: 6, 13, 84
30 CHRNB4 3件: Neuroactive ligand-receptor interaction, Cholinergic synapse, Chemical carcinogenesis - receptor activation D05157 Nicotine 3件: 6, 13, 84
31 CHRND 1件: Neuroactive ligand-receptor interaction D03365 Nicotine 1件: 84
32 CHRND 1件: Neuroactive ligand-receptor interaction D05156 Nicotine 1件: 84
33 CHRND 1件: Neuroactive ligand-receptor interaction D05157 Nicotine 1件: 84
34 CHRNE 1件: Neuroactive ligand-receptor interaction D03365 Nicotine 1件: 84
35 CHRNE 1件: Neuroactive ligand-receptor interaction D05156 Nicotine 1件: 84
36 CHRNE 1件: Neuroactive ligand-receptor interaction D05157 Nicotine 1件: 84
37 CHRNG 1件: Neuroactive ligand-receptor interaction D03365 Nicotine 1件: 84
38 CHRNG 1件: Neuroactive ligand-receptor interaction D05156 Nicotine 1件: 84
39 CHRNG 1件: Neuroactive ligand-receptor interaction D05157 Nicotine 1件: 84
40 CCR5 9件: Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, Chemokine signaling pathway, Endocytosis, Toxoplasmosis, Human cytomegalovirus infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Viral carcinogenesis D06670 Maraviroc 2件: 46, 84
41 DHFR 5件: One carbon pool by folate, Folate biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Antifolate resistance D00142 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331
42 DHFR 5件: One carbon pool by folate, Folate biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Antifolate resistance D02115 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331
43 EDNRA 7件: Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin secretion, Pathways in cancer D01227 Bosentan 11件: 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212
44 EDNRA 7件: Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin secretion, Pathways in cancer D07077 Ambrisentan 7件: 51, 84, 85, 86, 88, 210, 211
45 EDNRA 7件: Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin secretion, Pathways in cancer D07538 Bosentan 11件: 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212
46 EDNRB 6件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Melanogenesis, Relaxin signaling pathway, Pathways in cancer D01227 Bosentan 11件: 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212
47 EDNRB 6件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Melanogenesis, Relaxin signaling pathway, Pathways in cancer D07538 Bosentan 11件: 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212
48 DHFR2 5件: One carbon pool by folate, Folate biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Antifolate resistance D00142 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331
49 DHFR2 5件: One carbon pool by folate, Folate biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Antifolate resistance D02115 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331
50 MTOR 51件: EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, HIF-1 signaling pathway, Phospholipase D signaling pathway, Autophagy - other, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Cellular senescence, Apelin signaling pathway, Neutrophil extracellular trap formation, JAK-STAT signaling pathway, Th17 cell differentiation, Thermogenesis, Insulin signaling pathway, Thyroid hormone signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Growth hormone synthesis, secretion and action, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Shigellosis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Colorectal cancer, Pancreatic cancer, Glioma, Prostate cancer, Acute myeloid leukemia, Breast cancer, Hepatocellular carcinoma, Gastric cancer, Central carbon metabolism in cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Diabetic cardiomyopathy D00753 Sirolimus 41件: 2, 6, 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331
51 GABRA1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00549 Propofol 10件: 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
52 GABRA2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00549 Propofol 10件: 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
53 GABRA3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00549 Propofol 10件: 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
54 GABRA4 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00549 Propofol 10件: 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
55 GABRA5 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00549 Propofol 10件: 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
56 GABRA6 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00549 Propofol 10件: 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
57 GABRB1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol 10件: 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
58 GABRB2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol 10件: 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
59 GABRB3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol 10件: 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
60 GABRD 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol 10件: 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
61 GABRE 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol 10件: 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
62 GABRG1 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol 10件: 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
63 GABRG2 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol 10件: 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
64 GABRG3 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol 10件: 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
65 GABRP 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol 10件: 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
66 NR3C1 1件: Neuroactive ligand-receptor interaction D00292 Dexamethasone 11件: 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299
67 NR3C1 1件: Neuroactive ligand-receptor interaction D00407 Methylprednisolone 20件: 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300
68 NR3C1 1件: Neuroactive ligand-receptor interaction D00472 Prednisolone 16件: 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307
69 NR3C1 1件: Neuroactive ligand-receptor interaction D00473 Prednisone 22件: 84, 85, 86, 95, 96, 97, 113, 127, 162, 164, 205, 222, 224, 228, 251, 283, 284, 285, 288, 299, 300, 331
70 NR3C1 1件: Neuroactive ligand-receptor interaction D00751 Methylprednisolone 20件: 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300
71 NR3C1 1件: Neuroactive ligand-receptor interaction D00975 Dexamethasone 11件: 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299
72 NR3C1 1件: Neuroactive ligand-receptor interaction D00979 Methylprednisolone 20件: 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300
73 NR3C1 1件: Neuroactive ligand-receptor interaction D00980 Prednisolone 16件: 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307
74 NR3C1 1件: Neuroactive ligand-receptor interaction D00981 Prednisolone 16件: 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307
75 NR3C1 1件: Neuroactive ligand-receptor interaction D00982 Prednisolone 16件: 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307
76 NR3C1 1件: Neuroactive ligand-receptor interaction D01239 Prednisolone 16件: 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307
77 NR3C1 1件: Neuroactive ligand-receptor interaction D01510 Dexamethasone 11件: 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299
78 NR3C1 1件: Neuroactive ligand-receptor interaction D01615 Dexamethasone 11件: 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299
79 NR3C1 1件: Neuroactive ligand-receptor interaction D01632 Dexamethasone 11件: 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299
80 NR3C1 1件: Neuroactive ligand-receptor interaction D01703 Ciclesonide 1件: 84
81 NR3C1 1件: Neuroactive ligand-receptor interaction D01948 Dexamethasone 11件: 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299
82 NR3C1 1件: Neuroactive ligand-receptor interaction D01998 Prednisolone 16件: 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307
83 NR3C1 1件: Neuroactive ligand-receptor interaction D02156 Prednisolone 16件: 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307
84 NR3C1 1件: Neuroactive ligand-receptor interaction D02174 Dexamethasone 11件: 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299
85 NR3C1 1件: Neuroactive ligand-receptor interaction D02591 Dexamethasone 11件: 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299
86 NR3C1 1件: Neuroactive ligand-receptor interaction D02592 Dexamethasone 11件: 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299
87 NR3C1 1件: Neuroactive ligand-receptor interaction D03301 Prednisolone 16件: 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307
88 NR3C1 1件: Neuroactive ligand-receptor interaction D05000 Methylprednisolone 20件: 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300
89 NR3C1 1件: Neuroactive ligand-receptor interaction D05001 Methylprednisolone 20件: 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300
90 NR3C1 1件: Neuroactive ligand-receptor interaction D05002 Methylprednisolone 20件: 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300
91 GUCY1A2 11件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Gap junction, Platelet activation, Circadian entrainment, Long-term depression, Oxytocin signaling pathway, Renin secretion, Salivary secretion D09572 Riociguat 6件: 51, 84, 86, 88, 225, 299
92 GUCY1A1 11件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Gap junction, Platelet activation, Circadian entrainment, Long-term depression, Oxytocin signaling pathway, Renin secretion, Salivary secretion D09572 Riociguat 6件: 51, 84, 86, 88, 225, 299
93 GUCY1B1 11件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Gap junction, Platelet activation, Circadian entrainment, Long-term depression, Oxytocin signaling pathway, Renin secretion, Salivary secretion D09572 Riociguat 6件: 51, 84, 86, 88, 225, 299
94 HMGCR 4件: Terpenoid backbone biosynthesis, Metabolic pathways, AMPK signaling pathway, Bile secretion D00887 Atorvastatin 18件: 13, 46, 49, 51, 58, 63, 79, 84, 88, 93, 96, 97, 160, 222, 225, 265, 271, 299
95 HMGCR 4件: Terpenoid backbone biosynthesis, Metabolic pathways, AMPK signaling pathway, Bile secretion D07474 Atorvastatin 18件: 13, 46, 49, 51, 58, 63, 79, 84, 88, 93, 96, 97, 160, 222, 225, 265, 271, 299
96 IL1A 21件: MAPK signaling pathway, Cytokine-cytokine receptor interaction, Necroptosis, Cellular senescence, Osteoclast differentiation, Hematopoietic cell lineage, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Type I diabetes mellitus, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pertussis, Leishmaniasis, Tuberculosis, Measles, Influenza A, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Fluid shear stress and atherosclerosis D01583 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
97 IL1B 44件: Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Cytosolic DNA-sensing pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Inflammatory mediator regulation of TRP channels, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Amoebiasis, Tuberculosis, Measles, Human cytomegalovirus infection, Influenza A, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D01583 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
98 IL1B 44件: Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Cytosolic DNA-sensing pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Inflammatory mediator regulation of TRP channels, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Amoebiasis, Tuberculosis, Measles, Human cytomegalovirus infection, Influenza A, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D09315 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269
99 IL1R1 13件: MAPK signaling pathway, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Osteoclast differentiation, Hematopoietic cell lineage, Th17 cell differentiation, Inflammatory mediator regulation of TRP channels, Pathogenic Escherichia coli infection, Shigellosis, Amoebiasis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Fluid shear stress and atherosclerosis D02934 Anakinra 19件: 2, 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299
100 IL6 51件: EGFR tyrosine kinase inhibitor resistance, Antifolate resistance, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, HIF-1 signaling pathway, FoxO signaling pathway, PI3K-Akt signaling pathway, Cellular senescence, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Cytosolic DNA-sensing pathway, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Intestinal immune network for IgA production, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Chagas disease, African trypanosomiasis, Malaria, Amoebiasis, Tuberculosis, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer, Transcriptional misregulation in cancer, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Hypertrophic cardiomyopathy, Lipid and atherosclerosis D01583 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
101 IL6R 12件: EGFR tyrosine kinase inhibitor resistance, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, HIF-1 signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Th17 cell differentiation, Non-alcoholic fatty liver disease, Human cytomegalovirus infection, Coronavirus disease - COVID-19, Pathways in cancer D10161 Sarilumab 5件: 41, 46, 84, 107, 271
102 IL10 22件: Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, FoxO signaling pathway, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, T cell receptor signaling pathway, Intestinal immune network for IgA production, Pertussis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Staphylococcus aureus infection, Tuberculosis, Asthma, Autoimmune thyroid disease, Inflammatory bowel disease, Systemic lupus erythematosus, Allograft rejection D01583 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
103 IL12A 25件: Cytokine-cytokine receptor interaction, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Alcoholic liver disease, Type I diabetes mellitus, Pertussis, Legionellosis, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Measles, Influenza A, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Inflammatory bowel disease, Allograft rejection, Lipid and atherosclerosis D09214 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271
104 IL12B 25件: Cytokine-cytokine receptor interaction, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Alcoholic liver disease, Type I diabetes mellitus, Pertussis, Legionellosis, Leishmaniasis, Chagas disease, African trypanosomiasis, Toxoplasmosis, Amoebiasis, Tuberculosis, Measles, Influenza A, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Proteoglycans in cancer, Inflammatory bowel disease, Allograft rejection, Lipid and atherosclerosis D09214 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271
105 IMPDH1 3件: Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways D05096 Mycophenolic acid 36件: 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 84, 85, 93, 95, 96, 162, 164, 222, 224, 226, 228, 234, 283, 284, 285, 300
106 IMPDH2 3件: Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways D05096 Mycophenolic acid 36件: 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 84, 85, 93, 95, 96, 162, 164, 222, 224, 226, 228, 234, 283, 284, 285, 300
107 JAK1 27件: EGFR tyrosine kinase inhibitor resistance, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D09970 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271
108 JAK2 24件: EGFR tyrosine kinase inhibitor resistance, Chemokine signaling pathway, PI3K-Akt signaling pathway, Necroptosis, Signaling pathways regulating pluripotency of stem cells, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Cholinergic synapse, Prolactin signaling pathway, Adipocytokine signaling pathway, AGE-RAGE signaling pathway in diabetic complications, Growth hormone synthesis, secretion and action, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis B, Influenza A, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Pathways in cancer, Chemical carcinogenesis - receptor activation, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D09970 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271
109 JAK3 15件: Chemokine signaling pathway, PI3K-Akt signaling pathway, Necroptosis, Signaling pathways regulating pluripotency of stem cells, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Hepatitis B, Measles, Human T-cell leukemia virus 1 infection, Epstein-Barr virus infection, Pathways in cancer, Viral carcinogenesis, Non-small cell lung cancer, Primary immunodeficiency D09970 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271
110 MC2R 5件: cAMP signaling pathway, Neuroactive ligand-receptor interaction, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome D00146 Corticotropin 15件: 2, 13, 14, 46, 49, 50, 66, 75, 78, 81, 84, 145, 193, 205, 222
111 SERPINC1 1件: Complement and coagulation cascades D07510 Heparin 8件: 84, 107, 224, 226, 280, 299, 316, 317
112 PDE4A 5件: Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D05744 Roflumilast 2件: 84, 299
113 PDE4B 5件: Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D05744 Roflumilast 2件: 84, 299
114 PDE4C 5件: Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D05744 Roflumilast 2件: 84, 299
115 PDE4D 5件: Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D05744 Roflumilast 2件: 84, 299
116 IL23A 9件: Cytokine-cytokine receptor interaction, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Th17 cell differentiation, Pertussis, Tuberculosis, Pathways in cancer, Inflammatory bowel disease, Rheumatoid arthritis D09214 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271
117 CHRNA9 2件: Neuroactive ligand-receptor interaction, Chemical carcinogenesis - receptor activation D03365 Nicotine 3件: 6, 13, 84
118 CHRNA9 2件: Neuroactive ligand-receptor interaction, Chemical carcinogenesis - receptor activation D05156 Nicotine 3件: 6, 13, 84
119 CHRNA9 2件: Neuroactive ligand-receptor interaction, Chemical carcinogenesis - receptor activation D05157 Nicotine 3件: 6, 13, 84
120 GABRQ 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol 10件: 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
121 CHRNA10 1件: Neuroactive ligand-receptor interaction D03365 Nicotine 1件: 84
122 CHRNA10 1件: Neuroactive ligand-receptor interaction D05156 Nicotine 1件: 84
123 CHRNA10 1件: Neuroactive ligand-receptor interaction D05157 Nicotine 1件: 84
124 PTGIR 3件: Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Platelet activation D02721 Iloprost 4件: 51, 84, 85, 86
125 PTGIR 3件: Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Platelet activation D06213 Treprostinil 6件: 51, 84, 85, 86, 88, 210
126 PTGIR 3件: Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Platelet activation D09994 Selexipag 6件: 47, 51, 70, 84, 86, 88
127 SCN1A 1件: Dopaminergic synapse D00358 Lidocaine 7件: 84, 86, 107, 168, 226, 231, 256
128 SCN1A 1件: Dopaminergic synapse D02086 Lidocaine 7件: 84, 86, 107, 168, 226, 231, 256
129 SCN1A 1件: Dopaminergic synapse D08127 Lidocaine 7件: 84, 86, 107, 168, 226, 231, 256
130 SCN2A 1件: Taste transduction D00358 Lidocaine 7件: 84, 86, 107, 168, 226, 231, 256
131 SCN2A 1件: Taste transduction D02086 Lidocaine 7件: 84, 86, 107, 168, 226, 231, 256
132 SCN2A 1件: Taste transduction D08127 Lidocaine 7件: 84, 86, 107, 168, 226, 231, 256
133 SCN3A 1件: Taste transduction D00358 Lidocaine 7件: 84, 86, 107, 168, 226, 231, 256
134 SCN3A 1件: Taste transduction D02086 Lidocaine 7件: 84, 86, 107, 168, 226, 231, 256
135 SCN3A 1件: Taste transduction D08127 Lidocaine 7件: 84, 86, 107, 168, 226, 231, 256
136 SCN5A 1件: Adrenergic signaling in cardiomyocytes D00358 Lidocaine 7件: 84, 86, 107, 168, 226, 231, 256
137 SCN5A 1件: Adrenergic signaling in cardiomyocytes D02086 Lidocaine 7件: 84, 86, 107, 168, 226, 231, 256
138 SCN5A 1件: Adrenergic signaling in cardiomyocytes D08127 Lidocaine 7件: 84, 86, 107, 168, 226, 231, 256
139 SCN9A 1件: Taste transduction D00358 Lidocaine 7件: 84, 86, 107, 168, 226, 231, 256
140 SCN9A 1件: Taste transduction D02086 Lidocaine 7件: 84, 86, 107, 168, 226, 231, 256
141 SCN9A 1件: Taste transduction D08127 Lidocaine 7件: 84, 86, 107, 168, 226, 231, 256
142 CCL2 17件: Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, Chemokine signaling pathway, NOD-like receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, AGE-RAGE signaling pathway in diabetic complications, Yersinia infection, Chagas disease, Malaria, Human cytomegalovirus infection, Influenza A, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Rheumatoid arthritis, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D01583 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
143 SLC6A2 1件: Synaptic vesicle cycle D01296 Methylphenidate 4件: 84, 113, 179, 206
144 SLC6A2 1件: Synaptic vesicle cycle D04999 Methylphenidate 4件: 84, 113, 179, 206
145 SLC6A3 7件: Synaptic vesicle cycle, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Alcoholism D01296 Methylphenidate 7件: 6, 13, 34, 84, 113, 179, 206
146 SLC6A3 7件: Synaptic vesicle cycle, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Alcoholism D03215 Armodafinil 3件: 6, 13, 84
147 SLC6A3 7件: Synaptic vesicle cycle, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Alcoholism D04999 Methylphenidate 7件: 6, 13, 34, 84, 113, 179, 206
148 SSTR2 4件: cAMP signaling pathway, Neuroactive ligand-receptor interaction, Growth hormone synthesis, secretion and action, Gastric acid secretion D00442 Octreotide 7件: 67, 75, 84, 85, 89, 193, 227
149 SSTR2 4件: cAMP signaling pathway, Neuroactive ligand-receptor interaction, Growth hormone synthesis, secretion and action, Gastric acid secretion D06495 Octreotide 7件: 67, 75, 84, 85, 89, 193, 227
150 TNF 67件: Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D00754 Thalidomide 20件: 2, 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331
151 TNF 67件: Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D01583 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
152 TNF 67件: Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D02597 Adalimumab 18件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271
153 TNF 67件: Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D02598 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271
154 TNF 67件: Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D04358 Golimumab 8件: 46, 56, 84, 96, 97, 107, 270, 271
155 TYK2 16件: Necroptosis, Osteoclast differentiation, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Hepatitis C, Hepatitis B, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19 D09970 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271
156 VDR 5件: Parathyroid hormone synthesis, secretion and action, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Tuberculosis, Chemical carcinogenesis - receptor activation D00187 Ergocalciferol 6件: 46, 49, 84, 96, 97, 299
157 VDR 5件: Parathyroid hormone synthesis, secretion and action, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Tuberculosis, Chemical carcinogenesis - receptor activation D00188 Cholecalciferol 25件: 6, 13, 19, 20, 28, 34, 46, 49, 51, 53, 56, 60, 65, 75, 84, 85, 96, 97, 98, 162, 202, 228, 271, 298, 299
158 IL1R2 7件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Amoebiasis, Human T-cell leukemia virus 1 infection, Transcriptional misregulation in cancer, Prostate cancer, Fluid shear stress and atherosclerosis D02934 Anakinra 19件: 2, 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299
159 PDE5A 3件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway D02008 Tadalafil 7件: 6, 51, 75, 84, 86, 113, 210
160 CHRNA6 3件: Neuroactive ligand-receptor interaction, Cholinergic synapse, Nicotine addiction D03365 Nicotine 3件: 6, 13, 84
161 CHRNA6 3件: Neuroactive ligand-receptor interaction, Cholinergic synapse, Nicotine addiction D05156 Nicotine 3件: 6, 13, 84
162 CHRNA6 3件: Neuroactive ligand-receptor interaction, Cholinergic synapse, Nicotine addiction D05157 Nicotine 3件: 6, 13, 84
163 MS4A1 1件: Hematopoietic cell lineage D02994 Rituximab 21件: 84, 85, 86, 93, 94, 96, 97, 127, 162, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331
164 CD80 10件: Cell adhesion molecules, Toll-like receptor signaling pathway, Intestinal immune network for IgA production, Type I diabetes mellitus, Autoimmune thyroid disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Viral myocarditis D03203 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300
165 CD86 12件: Cell adhesion molecules, Toll-like receptor signaling pathway, Intestinal immune network for IgA production, Type I diabetes mellitus, Kaposi sarcoma-associated herpesvirus infection, Transcriptional misregulation in cancer, Autoimmune thyroid disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Viral myocarditis D03203 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300
166 NR1H4 1件: Bile secretion D00734 Ursodeoxycholic acid 9件: 84, 93, 94, 95, 96, 97, 234, 296, 299